Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4928378 | 1.00 | CSNK2A1 (0.38) | CSNK2A1CSNK2A2USP30EGFRBTK | |
| SCHEMBL26097719 | 0.88 | GRM5 (0.36) | CSNK2A1CSNK2A2USP30EGFRBTK | |
| SCHEMBL2492487 | 0.86 | FGFR4 (0.40) | CSNK2A1CSNK2A2USP30EGFRBTK | |
| SCHEMBL12405455 | 0.85 | CSNK2A1 (0.40) | CSNK2A1CSNK2A2USP30EGFRBTK | |
| SCHEMBL30918942 | 0.84 | CSNK2A1 (0.37) | CSNK2A1CSNK2A2USP30EGFRBTK | |
| SCHEMBL23530252 | 0.83 | CSNK2A1 (0.37) | CSNK2A1CSNK2A2USP30EGFRBTK | |
| SCHEMBL30918950 | 0.83 | FGFR4 (0.55) | CSNK2A1CSNK2A2USP30EGFRBTK | |
| SCHEMBL30895915 | 0.82 | FGFR4 (0.44) | CSNK2A1CSNK2A2USP30EGFRBTK | |
| SCHEMBL23554288 | 0.82 | CSNK2A1 (0.43) | CSNK2A1CSNK2A2USP30EGFRBTK | |
| SCHEMBL4207156 | 0.81 | CSNK2A1 (0.38) | CSNK2A1CSNK2A2USP30EGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4079734-B1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMR BIOTECHNOLOGY CO LTD (CN) | 2025-09-17 | — | — | EP | disclosed |
| EP-4608831-A1 | COMPOUNDS AND USES THEREOF | Suzhou Zanrong Pharma Limited (CN) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025099307-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2025-05-15 | — | — | WO | disclosed |
| WO-2024088351-A1 | COMPOUNDS AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2024-05-02 | — | — | WO | disclosed |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4079734-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | ABCG2, CYP4F8, CYP3A5 | CSNK2A1 2381/4885CSNK2A2 2657/4885USP30 4580/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | CSNK2A1 1415/4885CSNK2A2 1648/4885USP30 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.